Summary Four monoclonal antibodies (MAbs) from hybridoma obtained by in vitro stimulation of regional lymph node lymphocytes from lung cancer patients and electrofusion of the stimulated cells with murine or human -mouse myeloma cells were reactive to lung cancer cells in enzyme-linked immunoabsorbent assay, and to lung cancer tissue in immunohistochemical analysis using acetone-methyl benzoate-xylene (AMeX) fixed tissue and in immunofluorescence analysis. Three of the MAbs (designated ZLG40, 27D57 and 28K29) recognised cell-surface antigens of the lung adenocarcinoma cell line A549 and the remaining one (designated 29D38) recognised nuclear membrane antigens of the same cell line. The three surface-binding MAbs showed a significant complement-dependent cytotoxicity (CDC) to the A549 cells, but the membrane-binding 29D38 showed no CDC to the A549 cells. Western blotting of the extracts of the A549 or PC6 (small-cell lung cancer) cell lines by the four MAbs showed a 28K29 antigen band at M, of approximately 600 000 (± 2-ME), a ZLG40 antigen band at Mr 50 000 (±2-ME), and one 29D38 antigen band at Mr of more than 1 000 000 (-2-ME) and Mr between 20 000 and 80 000 (+ 2-ME), but no detectable band for 27D57 antigen.
It is widely recognised that human monoclonal antibodies (MAbs) specific for tumour-associated antigens and particularly for cell surface antigens may be useful as in vivo diagnostic or therapeutic tools, but efforts to obtain such antibodies have been hampered by difficulties in their detection and production (James et al., 1987; Hanna et al., 1991) . Screening for human MAbs is most commonly done by immunohistochemical staining using formalin-fixed and paraffin-embedded tissue sections of tumour specimens, but this has generally resulted in the detection of MAbs specific to cytoplasmic rather than cell surface antigens of cancer cells (Hanna et al., 1991) . Alternatively, frozen sections of tumour tissues have been used for detection of membrane-binding MAbs, but their preparation is generally difficult and timeconsuming and their microscopic observation is often ambiguous because of difficulties in their immobilisation on glass slides.
Sato et al. (1986) , on the other hand, have reported efficient detection of cell surface antigens of normal lymphocytes using acetone fixation followed by clearance of the acetone with methyl benzoate and xylene, largely free of the destruction of cell surface antigens that generally occurs with formalin fixation.
In the present study, we therefore investigated the use of this AMeX method in the screening of MAbs for binding to the membranes of cells from the tissue of lung cancer patients, in addition to the conventional formalin fixation and frozen tissue methods.
Human MAbs have been generated by various techniques, generally involving: (1) fusion of murine, human-mouse or human myeloma cells, originally developed by K6hler and Milstein (1975) ; (2) transplanting of MAb-producing human lymphocytes to severe combined immunodeficient (SCID) mice (McCune et al., 1988; Duchosal et al., 1992) ; or (3) phage display technology or genetic manipulation techniques (McCafferty et al., 1990; Zebedee et al., 1992; Green et al., 1994; Lonberg et al., 1994) . Among these methods, one of the most readily implemented is the fusion of human lymphocytes with murine or human-mouse myeloma cells, but it has commonly suffered from inefficiency in the establishment of MAb-producing hybridomas and instability in their MAb production. As previously reported, we have found it possible to increase the efficiency of establishment of such hybridoma by prior in vitro stimulation of the human lymphocytes with mitogens or interleukins (ILs) (James et al., 1987) , and to obtain stable MAb production by screening of the hybridomas for production of MAbs bearing A-chain as the L-chain subtype (Uchiyama et al., 1987; lizasa et al., 1990) .
Here we describe the investigation of the effectiveness of the use of the AMeX method in screening the MAbs for binding to cell surface and nuclear membrane antigens of cancer cells.
Materials and methods
Agents and cell lines LPS (Escherichia coli 0127:B8) and HAT were purchased from Sigma Chemical Co. (St Louis, MO, USA), SACI (Pansorbin cells 507861) from Calbiochem (San Diego, CA, USA), recombinant ILs and stem cell factor (SCF) from Genzyme (Cambridge, MA, USA), fetal calf serum (FCS) from Cytosystems (Castle Hill, Australia, cat. no. 15-010-0500V), and bovine insulin, human transferrin and sodium selenite from Cosmo-Bio Co. (Tokyo, Japan). The murine myeloma cell line P3X63Ag8.653, the human-mouse myeloma cell line SHM-D33, the human lung adenocarcinoma cell line A549, the human pancreas carcinoma cell line PANC-1, the human colon carcinoma cell line SW1222 and Correspondence: K Yoshinari, Asahi Chem Ind. Co. Ltd 632-1, Mifuku, Ohito-cho, Shizuoka 410-23, Japan the human lung diploid cell line W138 were obtained from the American Type Culture Collection (Rockville, MD, USA). The human lung adenocarcinoma cell lines PC9 and PC14, the human lung squamous carcinoma cell line QG56, the human lung large-cell carcinoma cell line PC13 and the human small-cell lung cancer cell line PC-6 were obtained from Immuno-Biological Laboratories (IBL) (Gunma, Japan). The human lung adenocarcinoma cell line PC3 and the human lung squamous carcinoma cell line EBC-1 were supplied by the Japanese Cancer Research Resources Bank (Tokyo, Japan). The ovarian carcinoma cell lines RMG-1 and RTSG were kindly supplied by Dr S Nozawa of Keio University (Tokyo, Japan).
Lymphocytes
Regional lymph nodes from patients with primary lung cancer were obtained aseptically at surgery. A single-cell suspension (lymphocytes) in 10% FCS-supplemented RPMI-1640 (Flow Laboratories) medium was prepared by passing the lymph nodes through sterile steel mesh (no. 200) after teasing with scissors.
In vitro stimulation of lymphocytes Lymphocytes (2.5 x 106 cells ml-') prewashed with PBS were resuspended in RDF medium (a 2:1:1 mixture of RPMI-1640, DMEM and Ham F12) (Murakami et al., 1985) with 10% FCS and 50 jgM 2-mercaptoethanol (2-ME). The cell suspension was pipetted at 2 ml per well into 6-well tissue culture plates and mitogens and ILs were added to the wells as indicated in Table I acetate, 0.5 mM Mg2' acetate and 1 mg ml-' BSA). After collection by low-speed centrifugation, cell pellets were resuspended in 2.5 ml of hypo-osmolar fusion medium (75L3; 70 mM sorbitol, 0.1 mM Ca2+ acetate, 0.5 mM Mg2+ acetate, and 1 mg ml-' BSA). Five minutes later, 0.83 ml aliquots of the cell suspension were placed in fusion chambers and exposed to one rectangular electrical pulse (1 MHz, 1.00 kV cm-', 15 jis) in the model SSH-1 cell fusion apparatus (Shimadzu Corporation, Kyoto, Japan). After another 5 min standing, the three aliquots of cell suspension (total volume 2.5 ml) were pipetted into 30 ml of HAT medium (RDF medium supplemented with 100 gM hypoxanthine, 16 gM thymidine, 0.2 jgM aminopterin, 5 jig ml-' bovine insulin, 5 jig ml-' human transferrin, 5 ng ml-' sodium selenite, 50 jiM 2-ME, 20 U ml-' IL-6, 40% BALB/c mouse splenocyte culture supernatant and 10% FCS) and then distributed in 0.1 ml portions into 96-well culture microplates. Plates were incubated for 2-4 weeks in humidified 5% carbon dioxide air at 37°C. Wells with growing colonies were selected microscopically, production of secreted immunoglobulin (Ig) was measured by a sandwich ELISA and Ig-secreting wells were maintained in HT medium (RDF medium supplemented with 100 gM hypoxanthine, 16 jiM thymidine, 5 jig ml-' bovine insulin, 5 ,ug ml-' human transferrin, 5 ng ml-' sodium selenite, 50 ,uM 2-ME, 20 U ml-' IL-6 and 10% FCS).
Cell culture and adaptation to serum-free medium Heterohybridomas secreting Ig with A-chain were screened in immunohistological and immunofluorescence methods as described below. The selected hybridomas secreting Ig reactive with lung cancer tissues and cell membrane or nuclear membrane of A549 cells were recloned three times by limiting dilution (0.5-2 cells ml-') in HT medium and finally adapted to a serum-free medium, Hybridoma-SFM (Gibco-BRL) supplemented with penicillin (50 IU ml-') and streptomycin (50 jig ml-'). For 28K29 and 28B49 (a negative control) cells, HT was further added to the serumfree medium. (Dorreen et al., 1982) . Then, the wells were washed three times with PBS containing 0.05% Tween 20 (Tween 20/PBS) and blocked with PBS containing 3% BSA.
After washing five times with PBS, 50 Ml aliquots of MAbcontaining samples were dispensed into each well. After incubation for 3 h at room temperature, the wells were washed three times with Tween 20/PBS, followed by the addition of alkaline phosphatase (ALP)-conjugated goat F(ab')2 anti-human Ig (Tago) diluted 1:1000 with 0.2% BSA-PBS. After incubation for 1 h, the wells were washed To prepare AMeX-fixed sections (Sato et al., 1986) , tissues were first fixed in acetone precooled to 4°C and stored at -20°C for 1-3 days. On removal from storage they were dehydrated by two cycles of acetone, followed by acetone removal in two cycles of 15 min immersion in methyl benzoate followed by 15 min in xylene, and then embedded in paraffin by the usual procedure. Sections (5 tm) of the paraffin-embedded tissues were taken, deparaffinised by xylene and acetone, and fixed in 4% PFA for 5 min. They were then prepared for staining by washing in water and PBS.
Formalin-fixed sections were prepared in the usual manner. Tissues were fixed in 10% formalin solution and embedded in paraffin, and sections (5 tim) of the embedded tissues were taken and then deparaffinised by xylene and ethanol in series and then washed in water and PBS.
In all three cases, immunostaining was performed as follows. The washed tissue sections were blocked with 10% normal goat serum (Nichirei, Tokyo, Japan) for 20 min at room temperature, followed by the addition of MAb (0.5-20 Mg ml-') test samples. After incubation for 18 h at 4°C in a moisturised atmosphere, the sections were washed three times with PBS. Peroxidase-conjugated goat F(ab')2 antihuman Ig (Cappel no. 3301-0231) diluted 1:1000 (v/v) in 0.2% BSA-PBS was layered on the washed sections. After incubation for 2 h at room temperature and washing three times with PBS, the sections were colorated with a substrate solution for peroxidase (0.02% diaminobenzidine and 0.005% hydrogen peroxide in 50 mM Tris-HCL buffer, pH 7.6), incubated for 5 min, washed with water, and counterstained with Harris-type haematoxylin solution (Sigma). The sections were then washed thoroughly with tap water and dehydrated with a graded series of ethanol and xylene. A cover glass was mounted on each slide with xylenebased Mount Quick (Daido-Sangyou, Tokyo, Japan), for microscopical observation.
Immunofluorescence A549 cells grown subconfluently in DMEM containing 10% FCS in T-75 culture bottles were incubated with PBS containing 0.02% EDTA for 10-20 min, then scraped and collected by centrifugation at low speed. Aliquots of 2 x 105 A549 cells were resuspended in 150 Ml supernatant containing MAb (0.5-20 Mg ml-'), followed by incubation for 2 h at 4°C. The cells were pelleted by centrifugation at low speed and resuspended in 100 pl of FITC-conjugated goat F(ab')2 anti-human Ig (Cappel). After incubation for 1 h at 4°C, the cells were washed three times with PBS and resuspended in 50 ,l of PBS for observation with an Axioscop (Zeiss, Germany) fluorescence microscope.
CDC activity A549 cells grown subconfluently in 10% FCS-supplemented DMEM in four T-75 culture bottles were collected as described above for immunofluorescence, and resuspended at a density of 1 x 106 cells ml-' in DMEM devoid of phenol red in the absence of FCS. Aliquots (100 Ml) of the cell suspension were dispensed in 96-well microplates and 10 Mg ml-' of each MAb and 10% low-toxic rabbit complement (Cederlane, Ontario, Canada) were added to each well, followed by incubation for 2 h at 37°C in humidified 5% carbon dioxide air. Viable cells were then counted by colorimetric assay using sodium 3'-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulphonic acid (XTT), Cell Proliferation kit II (Boehringer Mannheim, Germany) (Stevens et al., 1993; Buttke et al., 1993 Preparation of cell extracts Subconfluent A549 or PC-6 cells grown in 5% FCSsupplemented RDF medium in four T-75 culture bottles were collected as described in the section on immunofluorescence. Approximately 5-10 x 107 cells were resuspended in 1 ml of PBS containing 1% Triton X100, 5 Mg ml-1 leupeptin, 5 /g ml-' chymostatin, 5 Mg ml-' pepstatin and 1 mM phenylmethylsulphonyl fluoride (PMSF), and incubated for 45 min on ice with intermittent shaking. Supernatants were collected by centrifugation at 27 000 g for 5 min, detergent was removed with an SM-2 Econo-column (Japan Bio-Rad, Tokyo, Japan), and the cell extracts were used for immunoblotting.
Biotin labelling of MAb MAb solution purified from supernatants (2 1) of hybridoma grown in a serum-free medium using a hydroxylapatite column was buffer-exchanged to 50 mM bicarbonate buffer (pH 8.5) and concentrated to 2 mg ml-' with a Centricon-30 (Millipore). An aliquot (74 Ml) of 1 mg ml-' NHS-LC-biotin (Pierce, Rockford, IL, USA) was added, followed by incubation for 2 h on ice. The reaction mixture was centrifuged (10 000 g, 30 min) with a Centricon-30 to remove free biotin, and the concentrated solution was diluted in 10 mM phosphate buffer containing 150 mM sodium chloride and 0.1% sodium azide. The incubation- 
Results

Preliminary generation and screening
Electrofusion of the regional lymph node lymphocytes from seven patients with primary lung cancer, stimulated with mitogens or mitogens plus ILs, and the murine myeloma cell line (P3X63Ag8.653) or the human-mouse heteromyeloma cell line (SHM-D33) resulted in the generation of 2114 Igproducing hybridomas. The MAbs produced by these hybridomas were screened for (1) constituent A-chain; (2) reactivity in cell ELISA to the glutaraldehyde-fixed A549 lung adenocarcinoma cell line; (3) immunofluorescent staining of the A549 cell or nucleus membrane; and (4) immunohistochemical staining of the cancerous but not the non-cancerous parts of lung cancer tissue sections prepared by freezing, formalin fixation or AMeX fixation. Nine of the Ig-producing hybridomas satisfied all of these criteria, and four were prepared for the present study by recloning them three times and adapting them to the serum-free medium Hybridoma-SFM (GIBCO). Table I shows the lymphocytes, mitogens and ILs used to obtain these four hybridomas secreting human MAbs (ZLG40, 27D57, 28K29 and 29D38) showing specificity to lung cancer cells and tissue, together with those used to obtain the hybridoma cell line 28B49 as an isotype-matched negative control. As shown in Figure 1 , the four MAbs (1.0 jg ml-') selected from the screening all reacted with glutaraldehyde-fixed A549 cells grown in 96-well microplates, while the two controls 28B49 (IgM, A) and hIgM (human polyclonal IgM) showed no reactivity to the cells. Table II shows the results of cell ELISA using various human cell lines.
As illustrated in Figure 2a -d, immunofluorescent staining showed three of the four selected MAbs (28K29, 27D57 and ZLG40) to recognise A549 cell surface antigen, and the fourth MAb (29D38) recognised nuclear membrane antigen of the same cell line. No cellular fluorescence was observed with the control MAb, 28B49 (Figure 2e ).
Immunohistochemical study
The results of immunohistochemical staining with AMeX, frozen and formalin fixation are summarised in Table III. The MAb 28K29 reacted with most of the tissue sections of lung cancer tested, regardless of the fixation method, but the other three MAbs (ZLG40, 27D57, 29D38) reacted with EVQLV-QSGAQ-VXPPG-
-SVELT-QPPSG-SVSPG-KTARI-TCSGD-ALPKK-N-terminal amino acid sequences of five MAbs including the negative control 28B49 were determined. The known sequences of human germline V(H) (Berman et al., 1991) and human Ig (A) (Combriato et al., 1991) with high homology to the MAbs sequenced in this study were comparatively aligned.
tissue sections fixed by freezing and by AMeX, but not with those fixed by formalin.
Representative patterns of the staining with AMeX are shown in Figure 3 . All four MAbs reacted with the tissue sections fixed by this method. AMeX fixation resulted in a clear staining of cytoplasmic rather than cell surface regions (Figure 3a,c,d and e) by all four MAbs, and also an apparent staining of the luminal regions of membranes by the MAb 28K29 (Figure 3b) , indicating that the corresponding antigens to the four MAbs are localised in both membranous and cytoplasmic regions of cancer cells.
The four MAbs were also tested for immunoreactivity in frozen sections of normal mammary gland, stomach, lung and kidney tissues, with negative results in all cases. None of the four stained any of the cells of normal mammary ductal, gastric epithelial, bronchiolar epithelial or proximal tubular tissues (data not shown). 
CDC activity
The complement-dependent cytotoxicity of the four MAbs, as determined by incubating the A549 adenocarcinoma cells with the MAb (1 ,ug ml-') and 10% rabbit complement for 2 h at 37°C, counting the residual viable cells by the XTT method (Stevens et al., 1993; Buttke et al., 1993) , and calculating the CDC on this basis, is shown in Figure 4 . The CDC was high with the three cellular membrane-binding MAbs (approximately 30% with 28K29 and ZLG40 and approximately 12% with 27D57), but was only 3-6% with the nuclear membrane-binding MAb 29D38 and with the negative control MAb 28B49, and thus practically indistinguishable from background level CDC.
Antigen immunoblotting Antigens for three of the four MAbs were identified by immunoblotting, as shown in Figure 5 . The cell extracts were obtained from the lung adenocarcinoma cell line A549 and from the small-cell lung carcinoma cell line PC-6 by exposure to the detergent 1% Triton X100 and its removal with an SM-2 column. The cell extracts were run on 2-15% or 4-20% SDS-polyacrylamide gel, and the electrophoresed gel was blotted to PVDF membrane for the detection of bands immunoreactive to each MAb. The MAbs 28K29 and ZLG40 reacted with bands of approximately 600 000 and 50 000, respectively, under both non-reducing and reducing conditions. The MAb 29D38 bound to one or more substances of more than 1 000 000 at the gel top under non-reducing conditions, and to several bands between 20 000 and 80 000 under reducing conditions. The MAb 27D57 did not react with any band either the A549 or the PC-6 cell extract (data not shown). Table IV shows the results of the N-terminal sequencing of the four cell-reactive MAbs and the negative control 28B49, as determined by SDS-PAGE and the blotting to PVDF membrane followed by analysis with an automatic amino acid sequencer. The N-terminal amino acids of both the Hchain and the L-chain of MAb 28K29 were found to be blocked. The N-terminal amino acid sequences of the Lchains of 27D57, ZLG40 and 29D38 were identical as far as examined. As also shown in Table IV (Berman et al., 1991) , and between those of the L-chains of MAbs 29D38, 27D57 and ZLG40 and human Ig (A) (Combriato et al., 1991) .
N-terminal amino acid sequences
Discussion
The primary objective of the present study was the establishment of heterohybridoma cell lines producing human MAbs specific for cell-surface or nuclear membrane antigens of the lung adenocarcinoma cell line A549, from hybridomas generated by electrofusing the lymph node lymphocytes of lung cancer patients, stimulated in vitro with mitogens or mitogens plus lymphokines, with the readily available murine or human -mouse myeloma cells. A secondary objective, which proved important to the successful screening for such hybridomas, was the application of the AMeX method of Sato et al. (1986) to the fixation of solid tumour specimens consisting of cancerous tissues from lung cancer patients, to permit efficient detection of MAbs bound to cell-surface or nuclear membrane antigens.
In the effort to obtain human MAbs specific for tumourassociated antigens, immunohistochemical methods are generally preferable for the detection of cell-surface-binding MAbs. Among the several methods of tumour tissue fixation available for this purpose, formalin fixation has been most commonly employed because formalin-fixed tissue sections are easy to handle and familiar to many pathologists, even though it tends to involve inactivation or aggregation of the target antigens. Freezing has been used as an alternative method to avoid these problems, but immunohistochemical investigation of frozen tissue sections is often hindered by their fragility under the immunohistochemical staining procedure and by their incomplete or insecure immobilisation for microscopic observation.
The AMeX method was originally developed for the fixation of cell surface antigens of lymphocytes, but its adoption in the present study for the fixation of tissue sections of solid lung cancers showed it to be highly effective in screening for MAbs that recognise cell-surface or nuclear membrane antigens, as three of the four MAbs later 3 4 5 6 Figure 5 Immunoblotting analysis of antigens. Cell extracts of PC6 (lanes 1 and 2) and A549 (lanes 3 -6) were run on SDS-PAGE followed by Western blotting (lanes 1 and 2, 2-15% acrylamide gel; lanes 3-6, 4-20% acrylamide gel). The MAbs used were 28K29 (lane 1 and 2), ZLG40 (lane 3 and 4) and 29D38 (lanes 5 and 6). Lanes 1, 3 and 5 were obtained under non-reducing conditions and lanes 2, 4 and 6 under reducing conditions. SACI (Ruuskanen et al., 1980; Schuurman et al., 1980) but not by the polyclonal murine B cell activator LPS (Umetsu and Geha, 1987) .
In our own studies, however, we have chosen to employ LPS as well as SACI because regional lymph node lymphocytes, as our source of B cells, also include immune cells such as T cells and monocytes, and it therefore seemed reasonable to presume that indirect stimulation of human B cells might occur in the presence of LPS, probably via activation of monocytes which have been shown to have the cell-surface marker CD14, which is known as a receptor for LPS (Ziegler-Heitbrock et al., 1993) . The results of the present study indicate that LPS is effective for such activation, at least when used in combination with lymphokines such as IL-4, IL-6 and IL-7. On this basis, we have now begun a systematic study to determine the combinations of mitogens and lymphokines most effective for this purpose (Yoshinari et al., 1996) .
The productivity of the four hybridomas secreting reactive MAbs, following their recloning three times and adaptation to the serum-free medium Hybridoma-SFM (GIBCO-BRL), was: 29D38, 20-40 jug ml-'; 28K29 and 27D57, 5-20 tg ml-'; and ZLG40, 0.5-2 ,ug ml-'. Their MAb production in cell culture was found to be stable in the long term, for periods of up to 18 months or more. It may be noted, also, that the same hybridomas were found to be capable of producing MAbs in the ascites fluid of SCID mice following i.p. injection, at production levels of: 29D38, 20-40 mg per mouse; 28K29 and 27D57, 1-3 mg per mouse; ZLG40, less than 1 mg per mouse.
The results of the immunoblotting analyses provide certain insights into the identity and nature of the antigens for three of the four reactive MAbs. The analyses showed the 28K29 antigen to have Mr of approximately 600 000 on SDS-PAGE under both non-reducing and reducing conditions, thus suggesting that it may be a mucin-type tumour-associated antigen (Rughetti et al., 1993; Tytgat et al., 1994) . The ZLG40 antigen had Mr of 50 000 under both non-reducing and reducing conditions. Cytokeratins of 40-68 000 (Moll et al., 1982; Ramaekers et al., 1983; Haspel et al., 1985; Broers et al., 1988; Pomato et al., 1989; Erb et al., 1992) have been proposed as possible tumour-associated antigens, among which cytokeratins nos. 14 and 15 have Mr of 50 000. Against this, however, it must be noted that the immunofluorescence analyses showed the ZLG40 antigen to be localised at the cell surface of the A549 cells, thus suggesting that the ZLG40 antigen is not a cytokeratin as mentioned above.
The 29D38 antigen had M, of more than 1 000 000 under non-reducing conditions and between 20 000 and 80 000 in several major immunoreactive bands under reducing conditions. Recent findings show that 26S proteasome localised in the cytoplasm of cells has Mr of 2 000 000 and is comprised of several protein components ranging from 22 000 to 110 000 Mr (Peters et al., 1993 (Peters et al., , 1994 Rechsteiner et al., 1993; Rivett, 1993; Kristensen et al., 1994) . The immunofluorescence analysis, however, again showed that the 29D38 antigen was localised at the nuclear membrane of A549 cells, and thus suggested that the antigen would not be a proteasome itself, but that it may be a proteasome-like substance which is closely associated to tumour antigens. On the other hand, 27D57 antigen was not detected in cell extracts of A549 and PC6 cells. In summary, the results of the present study provide a basis for further study and characterisation of the antigens to three of the four MAbs, the exception being 27D57 antigen, which was not detected in the cell extracts of either A549 or PC6 by immunoblotting.
From the biological point of view, the results of the CDC activity were consistent with those of the immunofluorescence analyses. The three MAbs that bound to the cell surface of the A549 cells showed significant CDC to A549 cells, in varying degrees, while the MAb that bound to the nuclear membrane showed no CDC to A549 cells. In a related study now in progress, moreover, preliminary data on the biodistribution of the same human MAbs injected i.v. into A549 tumour cell burden SCID mice show significant accumulation of all four MAbs in the proliferated sites of A549 cells following their s.c. injection, but no such accumulation of a negative control MAb.
In conclusion, four human MAbs specific for cell surface or nuclear membrane of the lung adenocarcinoma cell line A549 were found and the heterohybridomas generating these MAbs were established, following their selection in an extensive screening of MAbs for A-chain constituents of their L-chain and reactivity to tissue sections of lung cancer prepared by AMeX fixation. The four heterohybridomas thus obtained were shown to be capable of efficient, stable longterm production of these MAbs, and AMeX fixation was shown to facilitate the detection of MAbs specific for cell surface and nuclear membrane antigens whose detection has heretofore been difficult or impossible. Abbreviations Ab, antibody; MAb, monoclonal antibody; LPS, lipopolysaccharide; SACI, Staphylococcus aureus Cowan I; IL, interleukin; DMEM, Dulbecco's minimum essential medium; FCS, fetal calf serum; BSA, bovine serum albumin; PFA, paraformaldehyde; SCLC, small-cell lung carcinoma; Ad, adenocarcinoma; Sq, squamous carcinoma; AMeX, acetone-methyl benzoate-xylene; 2-ME, 2-mercaptoethanol; CDC, complement-dependent cytotoxicity; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; XTT, sodium 3'-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulphonic acid.
